vTv Therapeutics Inc (VTVT)
23.63
-0.07
(-0.29%)
USD |
NASDAQ |
May 03, 16:00
23.70
+0.06
(+0.28%)
After-Hours: 20:00
vTv Therapeutics Research and Development Expense (Quarterly): 2.138M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.138M |
| September 30, 2023 | 2.824M |
| June 30, 2023 | 4.691M |
| March 31, 2023 | 3.942M |
| December 31, 2022 | 3.964M |
| September 30, 2022 | 3.055M |
| June 30, 2022 | 2.205M |
| March 31, 2022 | 3.133M |
| December 31, 2021 | 5.402M |
| September 30, 2021 | 2.382M |
| June 30, 2021 | 2.437M |
| March 31, 2021 | 3.103M |
| December 31, 2020 | 2.534M |
| September 30, 2020 | 1.768M |
| June 30, 2020 | 2.509M |
| March 31, 2020 | 4.204M |
| December 31, 2019 | 4.406M |
| September 30, 2019 | 3.663M |
| June 30, 2019 | 4.228M |
| March 31, 2019 | 2.822M |
| Date | Value |
|---|---|
| December 31, 2018 | 2.80M |
| September 30, 2018 | 2.698M |
| June 30, 2018 | 8.594M |
| March 31, 2018 | 8.943M |
| December 31, 2017 | 10.07M |
| September 30, 2017 | 8.989M |
| June 30, 2017 | 9.623M |
| March 31, 2017 | 10.96M |
| December 31, 2016 | 11.10M |
| September 30, 2016 | 11.16M |
| June 30, 2016 | 12.15M |
| March 31, 2016 | 11.34M |
| December 31, 2015 | 8.946M |
| September 30, 2015 | 7.159M |
| June 30, 2015 | 5.702M |
| March 31, 2015 | 7.776M |
| December 31, 2014 | 5.462M |
| September 30, 2014 | 4.328M |
| June 30, 2014 | 4.535M |
| March 31, 2014 | 4.404M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.768M
Minimum
Sep 2020
5.402M
Maximum
Dec 2021
3.294M
Average
3.103M
Median
Mar 2021
Research and Development Expense (Quarterly) Benchmarks
| Altimmune Inc | 16.91M |
| Palatin Technologies Inc | 5.554M |
| Oragenics Inc | 11.04M |
| Viking Therapeutics Inc | 24.10M |
| G1 Therapeutics Inc | 7.38M |